TherapeuticsMD reports third quarter 2026 results, notes new IMVEXXY milestone from KnightNov 13Quarterly updateestradiolTherapeuticsMD, Inc.
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
FDA approves first generic of Climara Pro hormone therapy patchOct 20Regulatory decisionBayerestradiol
Lilly advances obesity and inflammation pipeline with new Phase 1 trials, Phase 2 updatesOct 9Weekly roundup, 10 itemsEli Lillyeloralintide
Amneal wins REMS supplement approvals for two isotretinoin ANDAs, labeling update for valsartanOct 7Weekly roundup, 4 itemsAmneal Pharmaceuticals, LLCestradiol
GSK registers three new Phase 3 trials spanning asthma, prostate cancer, ovarian cancerOct 2Weekly roundup, 11 itemscabotegravirganfeboroleUpdated
Lilly registers three new early trials: olomorasib in colorectal cancer, two obesity studiesSep 11Weekly roundup, 3 itemsEli Lillyeloralintide
Vertex registers Phase 1 drug interaction study for VX-407 with oral contraceptivesAug 28Trial updateVertex Pharmaceuticals Inc / Ma
Dare Bioscience reports Q2 2026 results as first direct product launchesAug 13Quarterly updateDare Bioscience, Inc.
Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 updateAug 6Quarterly updatevareniclineViatris Inc.